Anna is Director of the Elizabeth Garrett Anderson Institute for Women’s Health at University College London (UCL) in London and an Honorary Consultant in Obstetrics and Maternal Fetal Medicine at UCL Hospital. Clinically she specializes in fetal medicine, severe congenital disease, fetal growth restriction and prevention of preterm birth. Her research team is developing novel prenatal therapies using stem cells and gene therapy. She led an international consensus to develop the first terminology to define and grade maternal and fetal adverse events for clinical trials in pregnancy: MFAET. She is also co-developing lactation adverse event terminology.